ObsEva (OBSV) Getting Negative Media Coverage, Study Shows
News stories about ObsEva (NASDAQ:OBSV) have trended negative recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ObsEva earned a news impact score of -0.29 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.6914095414626 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Several research analysts recently commented on OBSV shares. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of ObsEva in a research report on Wednesday, October 4th. Royal Bank of Canada reiterated a “buy” rating and issued a $22.00 price target on shares of ObsEva in a research report on Thursday, November 2nd. Zacks Investment Research upgraded ObsEva from a “sell” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Wednesday, October 18th. Credit Suisse Group started coverage on ObsEva in a research report on Monday, October 9th. They issued an “outperform” rating and a $16.00 price target for the company. Finally, BMO Capital Markets started coverage on ObsEva in a research report on Monday, December 4th. They issued an “outperform” rating and a $20.00 price target for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.00.
ObsEva (NASDAQ OBSV) opened at $9.64 on Tuesday. ObsEva has a 12-month low of $5.00 and a 12-month high of $14.69.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.